Astellas

Frequency bags $62M to advance Astellas-partnered hearing loss drug
Fierce Biotech
Tue, 07/23/19 - 10:10 am
Frequency Therapeutics
hearing loss
Astellas
FX-322
On heels of trial readout, Frequency out-licenses hearing loss therapy to Astellas
BioCentury
Wed, 07/17/19 - 10:46 am
Frequency Therapeutics
hearing loss
FX-322
Astellas
Why pharma needs honest patient dialogue
Pharmaforum
Sat, 07/13/19 - 11:14 am
Astellas
drug pricing
patients
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
Fierce Pharma
Sun, 06/2/19 - 01:17 pm
Pfizer
Astellas
Xtandi
prostate cancer
ASCO 2019
Feds say Astellas, Amgen will fork over $125M to settle charity kickback probes
Fierce Pharma
Thu, 04/25/19 - 06:49 pm
Astellas
Amgen
kickbacks
charity
DOJ
Xencor, Astellas Pharma collaborate on novel bispecific antibody program
Pharmaceutical Business Review
Wed, 04/3/19 - 10:00 am
Xencor
Astellas
R&D
bispecific antibodies
AACR: Astellas pads Xospata's AML lead with chemo-beating survival data
Fierce Pharma
Mon, 04/1/19 - 12:38 pm
Astellas
Xospata
acute myeloid leukemia
AML
AACR
Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody
Endpoints
Thu, 03/28/19 - 10:11 am
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
Bayer files prostate cancer drug darolutamide in Japan
Pharmaforum
Tue, 03/5/19 - 10:02 am
Bayer
prostate cancer
darolutamide
Japan
JNJ
Pfizer
Astellas
Pfizer, Astellas chase new Xtandi nod with big survival numbers in prostate cancer
Fierce Pharma
Tue, 02/12/19 - 12:01 pm
Xtandi
Astellas
Pfizer
hormone-sensitive prostate cancer
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
CP Wire
Thu, 12/20/18 - 10:27 am
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Thu, 12/20/18 - 10:19 am
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Astellas gains three cancer drugs with $405m Potenza buy
Pharmaforum
Fri, 12/14/18 - 12:47 pm
Astellas
Potenza Therapeutics
M&A
cancer immunotherapy
FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals
Endpoints
Thu, 11/29/18 - 12:10 am
Astellas
FDA
AML
Xospata
gilteritinib
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
Sun, 09/16/18 - 02:16 pm
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Yahoo/Reuters
Wed, 08/22/18 - 06:05 pm
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Linzess Receives Additional Indication in Japan for Chronic Constipation
CP Wire
Tue, 08/21/18 - 10:05 am
Linzess
Astellas
Ironwood
chronic constipation
Linzess Receives Additional Indication in Japan for Chronic Constipation
Tue, 08/21/18 - 09:38 am
Astellas
Ironwood Pharmaceuticals
Linzess
Astellas grabs a biotech toddler in $109M buyout deal for a glaucoma gene therapy program
Endpoints
Fri, 08/10/18 - 09:12 am
Astellas
glaucoma
Quethera
Astellas exploring selling Europe assets for $500m
GoinPharma
Fri, 07/20/18 - 09:41 am
Astellas
Europe
M&A

Pages